Axsome Therapeutics Company Leadership

AXSM Stock  USD 91.94  1.75  1.87%   
Axsome Therapeutics' insiders are aggressively selling. The analysis of insiders' sentiment of trading Axsome Therapeutics stock suggests that most insiders are panicking at this time. Axsome Therapeutics employs about 607 people. The company is managed by 9 executives with a total tenure of roughly 8 years, averaging almost 0.0 years of service per executive, having 67.44 employees per reported executive.

Axsome Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-09-11Mark E SaadDisposed 11016 @ 91.31View
2024-08-09Mark L JacobsonDisposed 47739 @ 84.26View
2024-05-29Mark L JacobsonDisposed 7910 @ 74.31View
2024-05-28Mark ColemanDisposed 5249 @ 75.21View
2024-04-01Mark L. JacobsonDisposed 24662 @ 77.24View
2024-03-14Roger JeffsDisposed 29976 @ 69.7View
Monitoring Axsome Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.

Axsome Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Axsome Therapeutics' future performance. Based on our forecasts, it is anticipated that Axsome will maintain a workforce of about 610 employees by February 2025.
 
Yuan Drop
 
Covid

Axsome Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2644) % which means that it has lost $0.2644 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7161) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of January 2025, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -0.49. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 19th of January 2025, Intangibles To Total Assets is likely to grow to 0.18, while Return On Tangible Assets are likely to drop (0.43).
As of the 19th of January 2025, Common Stock Shares Outstanding is likely to drop to about 30.1 M. In addition to that, Net Loss is likely to grow to about (160 M)

Axsome Therapeutics Workforce Comparison

Axsome Therapeutics is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 8,331. Axsome Therapeutics holds roughly 607 in number of employees claiming about 7% of equities under Health Care industry.

Axsome Therapeutics Profit Margins

The company has Profit Margin (PM) of (0.92) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.44) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.44.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.720.81
Fairly Down
Slightly volatile

Axsome Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Axsome Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
1.0
1
1
 33,410 
 33,410 
2024-09-01
0.5
2
4
 58,755 
 117,510 
2024-06-01
1.0
6
6
 61,551 
 81,424 
2024-03-01
2.8
14
5
 302,433 
 51,646 
2023-09-01
0.3333
1
3
 11,016 
 40,604 
2023-03-01
12.0
12
1
 365,480 
 17,501 
2022-06-01
1.3333
4
3
 67,904 
 120,081 
2022-03-01
7.0
7
1
 246,542 
 3,496 
2020-09-01
1.0
1
1
 397,998 
 397,998 
2020-03-01
1.4615
19
13
 647,821 
 424,355 
2019-09-01
1.6667
5
3
 183,800 
 56,620 
2017-03-01
5.0
10
2
 342,534 
 42,538 
2015-12-01
2.5
20
8
 1,067,394 
 234,153 

Axsome Therapeutics Notable Stakeholders

An Axsome Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Axsome Therapeutics often face trade-offs trying to please all of them. Axsome Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Axsome Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Herriot MDFounder, Chairman and CEOProfile
Mark JacobsonSenior Director - OperationsProfile
MB CPADirector FinanceProfile
Hunter EsqGeneral SecretaryProfile
Amanda PharmDSenior DevelopmentProfile
Lori MBAExecutive DevelopmentProfile
Kevin PharmDEx StrategyProfile
Mark MAChief OfficerProfile
Ari MaizelExecutive CommercialProfile

About Axsome Therapeutics Management Performance

The success or failure of an entity such as Axsome Therapeutics often depends on how effective the management is. Axsome Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Axsome management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Axsome management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.41)(0.43)
Return On Capital Employed(0.46)(0.49)
Return On Assets(0.37)(0.38)
Return On Equity(1.44)(1.37)

Axsome Therapeutics Workforce Analysis

Traditionally, organizations such as Axsome Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Axsome Therapeutics within its industry.

Axsome Therapeutics Manpower Efficiency

Return on Axsome Therapeutics Manpower

Revenue Per Employee445.8K
Revenue Per Executive30.1M
Net Loss Per Employee394.1K
Net Loss Per Executive26.6M
Working Capital Per Employee602K
Working Capital Per Executive40.6M
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.45)
Revenue Per Share
7.108
Quarterly Revenue Growth
0.813
Return On Assets
(0.26)
Return On Equity
(1.72)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.